Combination therapy with everolimus and tacrolimus in kidney transplantation recipients: A systematic review

Authors

  • Ali Akbari Sari Health Management and Economics Dept., Tehran University of Medical Sciences, Tehran, I.R. Iran
  • Mitra Mahdavi-Mazdeh Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran
  • Morteza Arab Zozani Iranian Center of Excellence in Health Management, Tabriz University of Medical Sciences, Tabriz, I.R. Iran
  • Reza Majdzadeh School of Public Health and Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran
Abstract:

Background and aims: Immunosuppressive regimens are a key component for successful kidney transplantation. This systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. Methods: Results were limited to English-language articles. Trials where recipients received another regimen were excluded. The Cochrane Central Register of Controlled Trials and MEDLINE were searched via the optimally sensitive strategies for the identification of randomized trials, combined with the following MeSH headings and text words: Everolimus, Certican, Zortress, tacrolimus, prograf, and kidney transplantation. Results: Five relevant studies of everolimus in combination with tacrolimus were identified and results of them were interpreted. Two trials investigated Fix dose of everolimus in combination with low (1.5-3 mg) versus standard dose of tacrolimus (4-7 mg). One trial investigated variable doses of everolimus (1.5 mg/day or 3 mg/day) in combination with fix dose of tacrolimusand two trials compared fix dose of everolimus versus reduction or elimination of tacrolimus. Sample size of RCTs ranged from 20 to 398 and the follow up time ranged from six to 24 months. The quality score on the Jadad score was 3 in all five trials indicating moderate quality. Conclusion: Immune suppressive regimens including everolimus in combination with tacrolimus therapy show better safety and efficacy compared with single-mode but these differences were not significant in overall studies. In general, compared with a regimen without combination of everolimus with tacrolimus, the newer immunosuppressive regimen consistently reduced the incidence of short-term biopsy-proven acute rejection. However, evidence about impact on side-effects, long term graft loss, compliance and overall health-related quality of life is limited.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

combination therapy with everolimus and tacrolimus in kidney transplantation recipients: a systematic review

background and aims: immunosuppressive regimens are a key component for successful kidney transplantation. this systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. methods: results were limited to english-language articles. trials where recipients received another regimen were excluded. the cochrane...

full text

Systematic conversion to generic tacrolimus in stable kidney transplant recipients

BACKGROUND Tacrolimus (Prograf®) is a key drug in the immunosuppressive treatment of renal transplant patients. Since the expiration of the patent for Prograf®, generic preparations have been approved in Europe as bioequivalence has been shown in healthy volunteers. However, few studies have investigated whether patients can be successfully converted from Prograf® to generic tacrolimus. Tacroli...

full text

Tacrolimus and diabetic ketoacidosis after kidney transplantation in a 15-year-old girl (Case Report)

Tacrolimus is a main drug for induction and maintenance immunosuppression for patients with kidney transplants in many centers. One of important side effect of drug is post-transplant diabetes mellitus. Of course, diabetes ketoacidosis (DKA) is rare. In this report, a 12-year-old girl with DKA was presented after 45 days of kidney transplantation. 

full text

Clinical experience of tacrolimus with everolimus in heart transplantation.

BACKGROUND Tacrolimus (Tac) in combination with mycophenolate mofetil is widely used after heart transplantation (HT). Everolimus (EVR), a new potent proliferation signal inhibitor can be used with a carcineurin inhibitor to reduce the occurrence of rejection. The purpose of this study was to evaluate the efficacy and safety of Tac combined with EVR in de novo HT. MATERIALS AND METHODS From J...

full text

ایمنی و اثربخشی داروی اورولیموس در مقایسه با تاکرولیموس و سیرولیموس در جلوگیری از رد پیوند کلیه: یک مطالعه مروری نظام‌مند و متاآنالیز

Background: Everolimus is an immunosuppressive agent with a novel mode of action but has a different clinical role with calcineurin inhibitors (CNI). The aim of this study was to evaluate the safety and effectiveness of everolimus compared with sirolimus and tacrolimus in preventing kidney transplantation rejection. Methods: Search was conducted for finding randomized clinical trials (RCT) unt...

full text

Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review.

BACKGROUND A simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily tacrolimus administration. METHODS We systematically reviewed all randomized controlled trials...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 1

pages  84- 90

publication date 2017-02-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023